Psychiatric Services
Journal Home Search Current Issue Past Issues Subscribe All APPI Journals Help Contact Us
 
Quicksearch
Advanced Search
Or Search All APPI Journals
This Article
* Full Text (PDF)
* Alert me when this article is cited
* Alert me if a correction is posted
Services
* Email this article to a Colleague
* Similar articles in this journal
* Similar articles in PubMed
* Alert me to new issues of the journal
* Add to My Articles & Searches
* Download to citation manager
* reprints & permissions
Citing Articles
* Citing Articles via Google Scholar
Google Scholar
* Articles by Knoth, R. L.
* Articles by Tafesse, E.
* Search for Related Content
PubMed
* PubMed Citation
* Articles by Knoth, R. L.
* Articles by Tafesse, E.
Related Collections
* Costs, Cost Analysis
* Bipolar Disorder
Psychiatr Serv 55:1353, December 2004
© 2004 American Psychiatric Association


Columns

Datapoints: Costs Associated With the Treatment of Patients With Bipolar Disorder in a Managed Care Organization

Russell L. Knoth, Ph.D., Kristina Chen, Pharm.D., M.S. and Eskinder Tafesse, Ph.D.


  Introduction

 
 TOP
 Introduction
 References
 
The estimated lifetime prevalence of bipolar disorder in the United States is currently 1 to 1.5 percent (1). Economic studies have shown that the treatment of bipolar disorder is associated with substantial costs to patients, their families, and society as a whole (2). Estimates from economic models have put the costs of bipolar disorder between $24 billion and $45 billion each year (3).

Our study examined the direct health care expenditures incurred by patients in a managed care plan in the first year after diagnosis of bipolar disorder from the payer's perspective. This study used a retrospective analysis of pharmacy and medical claims from a large network-model managed care organization that represents 2.7 million members in the United States.

Adult patients were identified who had at least one medical claim with a primary diagnosis of bipolar disorder (ICD-9-CM codes 296.40 to 296.99) between July 1, 2000, and June 30, 2001. The date of the first diagnosis in this period served as the index date. Patients were excluded from the analysis if they had been given a diagnosis of bipolar disorder in the year before the index date or if they were not continuously enrolled in the health plan in the year before and the year after the index date.

A total of 4,397 patients met the study criteria. The mean±SD age of the identified patients was 53.1±16.9 years, and 66.1 percent were female.

Figure 1 shows that total health care costs for identified patients in the first year after diagnosis were $19,116 per patient, compared with the total health care costs of $4,348 that the average member in the health plan incurred. Inpatient costs accounted for the largest proportion of incurred costs (56.7 percent), followed by charges for outpatient physician visits (26.4 percent).



View larger version (17K):
[in this window]
[in a new window]
 

Figure 1. Distribution of health care costs incurred by patients in a managed care plan in the first year after diagnosis of bipolar disorder



In the first year after the initial diagnosis of bipolar disorder, the patients in our study incurred nearly $85 million in annual health care costs. Of this, only 25 percent was related to mental health services. The fact that patients with bipolar disorder incurred more than four times the health care charges of the average member in the health plan speaks to the need for innovative and creative programs to manage this population.


  Acknowledgment

 
This research was supported in part by Bristol-Myers Squibb.


  Footnotes

 
Dr. Knoth is a senior research scientist in the pharmacoeconomics and health outcomes research group at Prescription Solutions, 3515 Harbor Boulevard, Costa Mesa, California 92626 (e-mail, rlknoth{at}hotmail.com). Dr. Chen is a senior research associate with Cerner Health Insights in Beverly Hills, California. Dr. Tafesse is the associate director of global epidemiology and outcomes research at Bristol-Myers Squibb in Wallingford, Connecticut. Harold Alan Pincus, M.D., and Terri L. Tanielian, M.A., are editors of this column.


  References

 
 TOP
 Introduction
 References
 

  1. Kessler RC, McGonagle KA, Zhao S, et al: Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Co-Morbidity Survey. Archives of General Psychiatry 51:8–19, 1994[Abstract/Free Full Text]
  2. Stimmel GL: The economic burden of bipolar disorder. Psychiatric Services 55:117–118, 2004[Free Full Text]
  3. Begley CE, Annegers JF, Swann AC, et al: The lifetime cost of bipolar disorder in the US: an estimate for new cases in 1998. Pharmacoeconomics 19:483–495, 2001[CrossRef][Medline]




This Article
* Full Text (PDF)
* Alert me when this article is cited
* Alert me if a correction is posted
Services
* Email this article to a Colleague
* Similar articles in this journal
* Similar articles in PubMed
* Alert me to new issues of the journal
* Add to My Articles & Searches
* Download to citation manager
* reprints & permissions
Citing Articles
* Citing Articles via Google Scholar
Google Scholar
* Articles by Knoth, R. L.
* Articles by Tafesse, E.
* Search for Related Content
PubMed
* PubMed Citation
* Articles by Knoth, R. L.
* Articles by Tafesse, E.
Related Collections
* Costs, Cost Analysis
* Bipolar Disorder


Get information about faster international access.

Privacy Policy

Copyright © 2004 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us

American Psychiatric Publishing, Inc. American Psychiatric Association
1000 Wilson Boulevard, Suite 1825, Arlington, VA 22209-3901 * 800-368-5777 * appi at psych.org